Q-omics provides the consensus-scored VTRNA1-3 profile across patient tissues and cancer cell-line models. VTRNA1-3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, VTRNA1-3 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, VTRNA1-3 RNA expression shows 11,688 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight MESO, THCA, and CCRCC as cancer lineages where VTRNA1-3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VTRNA1-3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VTRNA1-3 survival associations across molecular data types. VTRNA1-3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VTRNA1-3 RNA expression–survival associations across cancer types. High VTRNA1-3 expression shows unfavorable associations in MESO, STAD, KIRC, LGG, HNSC and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify MESO as the clearest survival context for VTRNA1-3 RNA expression.
This table summarizes VTRNA1-3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for VTRNA1-3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VTRNA1-3 shows lower tumor expression in THCA, LUAD, BRCA, STAD, LUSC and READ. The THCA box plot shows higher VTRNA1-3 RNA expression in normal versus tumor tissue (log2 FC = −1.180, t-test p < 0.001).
This table shows molecular features associated with VTRNA1-3 in patient tissues and cancer cell lines. In patient samples, VTRNA1-3 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
